Pharvaris BV (PHVS)
$18.40 -$0.44 (-2.31%) 4:38 PM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$1.03B -
Day's Range
$17.93 - $19.60 -
Volume
127,069 -
52 Week Low / High
$15.37 - $33.00 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
PHVS's Dividend
Hypothetical 10k Investment Jan 1, 2020
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Analyists Ranking
- 4
- Strong Buy
- 2
- Buy
- 0
- Hold
- 1
- Sell
- 0
- Strong Sell
- $24.15
- Target Price
Company News
-
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 — Mar 5th, 2024
Pharvaris N.V. ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that its management will participate i...
|
Portfolio
$5,000/year
Goal: $10,000/year
Comprised of 1 portfolios
$